All Blogs

Apr 23, 2024

Ipsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the ...

Sep 04, 2024

Liver disease emerges as a burgeoning global health concern, presenting a myriad of formidable challenges. From viral hepatitis to alcoholic liver disease, nonalcoholic fatty liver disease (NAFLD), liver cirrhosis, and hepatocellular carcinoma (HCC), these conditions collectively afflict millions, exacting a toll o...

Apr 22, 2024

NeuroDerm's ND0612 introduces a pioneering approach to Parkinson's disease management with its self-administered continuous subcutaneous infusion of levodopa/carbidopa. Unlike traditional oral formulations, ND0612 bypasses the gastrointestinal tract, offering increased bioavailability and potentially more reliable...

Apr 22, 2024

ZEPOSIA (ozanimod), a breakthrough approved in March 2020 for Relapsing Forms of Multiple Sclerosis (RMS), utilizes oral sphingosine 1-phosphate (S1P) receptor modulation to impede lymphocyte migration, offering a novel approach in multiple sclerosis treatment. ENLIGHTEN (NCT04140305) explores ozanimod's impact...

Apr 22, 2024

UB-312 represents a promising avenue in Parkinson's disease (PD) treatment by focusing on pathological forms of alpha-synuclein (aSyn), a key protein associated with the progression of synucleinopathies. Unlike conventional approaches, UB-312 aims to elicit antibodies that specifically recognize and neutralize the...

Apr 22, 2024

AXS-07, a cutting-edge oral solution, blends MoSEIC meloxicam and rizatriptan, offering rapid absorption. It ingeniously inhibits CGRP release, counteracting vasodilation, and curbing neuroinflammation and pain transmission for enhanced relief. AXS-07 demonstrates superior efficacy in swiftly alleviating migrai...

Apr 22, 2024

Frexalimab (SAR441344) is a novel anti-CD40L antibody in development, designed to inhibit the CD40/CD40L pathway, a crucial element in activating both adaptive and innate immune responses. Its distinctive mode of action targets neuroinflammation in multiple sclerosis, offering potential benefits for both acute and...

Apr 22, 2024

IPX203 represents a groundbreaking advancement in Parkinson's disease (PD) treatment with its novel oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules. Unlike existing options, IPX203 utilizes a unique combination of immediate-release granules and extended-release coated beads to provide both ...

Apr 18, 2024

Baxter Introduced New Injectable Pharmaceuticals to US Market On April 11, 2024, the pharmaceutical portfolio of multinational medical goods corporation Baxter International Inc. was augmented with the introduction of five new injectable medications in the US market. The goods were made to fulfill essential dema...

Apr 19, 2024

Eculizumab (SOLIRIS) and ravulizumab (ULTOMIRIS) are two approved therapies for the treatment for adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor antibody-positive. The findings presented by Alexion, AstraZeneca Rare Disease unveil a remarkable decline in Myasthenia G...